Subjects

Abstract

Genome-wide copy number analyses of human cancers identified a frequent 5p13 amplification in several solid tumour types, including lung (56%), ovarian (38%), breast (32%), prostate (37%) and melanoma (32%). Here, using integrative analysis of a genomic profile of the region, we identify a Golgi protein, GOLPH3, as a candidate targeted for amplification. Gain- and loss-of-function studies in vitro and in vivo validated GOLPH3 as a potent oncogene. Physically, GOLPH3 localizes to the trans-Golgi network and interacts with components of the retromer complex, which in yeast has been linked to target of rapamycin (TOR) signalling. Mechanistically, GOLPH3 regulates cell size, enhances growth-factor-induced mTOR (also known as FRAP1) signalling in human cancer cells, and alters the response to an mTOR inhibitor in vivo. Thus, genomic and genetic, biological, functional and biochemical data in yeast and humans establishes GOLPH3 as a new oncogene that is commonly targeted for amplification in human cancer, and is capable of modulating the response to rapamycin, a cancer drug in clinical use.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    & AKT/PKB signaling: navigating downstream. Cell 129, 1261–1274 (2007)

  2. 2.

    , & TOR signaling in growth and metabolism. Cell 124, 471–484 (2006)

  3. 3.

    et al. Disruption of the p70s6k/p85s6k gene reveals a small mouse phenotype and a new functional S6 kinase. EMBO J. 17, 6649–6659 (1998)

  4. 4.

    et al. Drosophila S6 kinase: a regulator of cell size. Science 285, 2126–2129 (1999)

  5. 5.

    , , , & Genetic and biochemical characterization of dTOR, the Drosophila homolog of the target of rapamycin. Genes Dev. 14, 2689–2694 (2000)

  6. 6.

    , , , & Regulation of cellular growth by the Drosophila target of rapamycin dTOR. Genes Dev. 14, 2712–2724 (2000)

  7. 7.

    & Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23, 3151–3171 (2004)

  8. 8.

    & Defining the role of mTOR in cancer. Cancer Cell 12, 9–22 (2007)

  9. 9.

    & Expanding mTOR signaling. Cell Res. 17, 666–681 (2007)

  10. 10.

    & Immunopharmacology of rapamycin. Annu. Rev. Immunol. 14, 483–510 (1996)

  11. 11.

    mTOR and cancer: insights into a complex relationship. Nature Rev. Cancer 6, 729–734 (2006)

  12. 12.

    et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436, 117–122 (2005)

  13. 13.

    et al. GMx33: a novel family of trans-Golgi proteins identified by proteomics. Traffic 1, 963–975 (2000)

  14. 14.

    et al. Proteomics characterization of abundant Golgi membrane proteins. J. Biol. Chem. 276, 5152–5165 (2001)

  15. 15.

    , , & GMx33 associates with the trans-Golgi matrix in a dynamic manner and sorts within tubules exiting the Golgi. Mol. Biol. Cell 17, 511–524 (2006)

  16. 16.

    & Retromer. Curr. Opin. Cell Biol. 20, 427–436 (2008)

  17. 17.

    et al. Insights into TOR function and rapamycin response: chemical genomic profiling by using a high-density cell array method. Proc. Natl Acad. Sci. USA 102, 7215–7220 (2005)

  18. 18.

    , & Automated subcellular localization and quantification of protein expression in tissue microarrays. Nature Med. 8, 1323–1327 (2002)

  19. 19.

    , , , & Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev. 16, 1472–1487 (2002)

  20. 20.

    , , , & RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc. Natl Acad. Sci. USA 95, 1432–1437 (1998)

  21. 21.

    et al. Immunopurified mammalian target of rapamycin phosphorylates and activates p70 S6 kinase α in vitro. J. Biol. Chem. 274, 34493–34498 (1999)

  22. 22.

    & mTOR·RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3–L1 adipocytes. J. Biol. Chem. 280, 40406–40416 (2005)

  23. 23.

    , , & Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098–1101 (2005)

  24. 24.

    et al. Ras signalling on the endoplasmic reticulum and the Golgi. Nature Cell Biol. 4, 343–350 (2002)

  25. 25.

    Retromer retrieves wntless. Dev. Cell 14, 4–6 (2008)

  26. 26.

    et al. Drosophila Vps35 function is necessary for normal endocytic trafficking and actin cytoskeleton organisation. J. Cell Sci. 120, 4367–4376 (2007)

  27. 27.

    et al. Golgi localization of glycosyltransferases requires a Vps74p oligomer. Dev. Cell 14, 523–534 (2008)

  28. 28.

    , , & Signal-mediated dynamic retention of glycosyltransferases in the Golgi. Science 321, 404–407 (2008)

  29. 29.

    & Glycosylation in cellular mechanisms of health and disease. Cell 126, 855–867 (2006)

  30. 30.

    , , , & Role of N-glycans in growth factor signaling. Glycoconj. J. 20, 207–212 (2004)

  31. 31.

    et al. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature 447, 966–971 (2007)

  32. 32.

    et al. Melanoma cell lines from different stages of progression and their biological and molecular analyses. Melanoma Res. 7 (suppl. 2). S35–S42 (1997)

  33. 33.

    et al. High-resolution genomic profiles of human lung cancer. Proc. Natl Acad. Sci. USA 102, 9625–9630 (2005)

Download references

Acknowledgements

We thank R. DePinho for critical reading of the manuscript, and L. Cantley, as well as members of the Chin laboratory, for helpful discussion. We thank H. Ying for assistance with confocal microscopy. The rabbit polyclonal antibody against human GOLPH3 was kindly provided by J. J. Bergeron of McGill University. Mouse monoclonal antibody against human GOLPH3, C19, was generated at the Dana-Farber/Harvard Cancer Center Monoclonal Antibody Core Facility. K.L.S. is at present supported by a Postdoctoral Fellowship from the American Cancer Society (PF-07-039-01-CSM), and K.L.S. and O.K. were previously supported by a National Institutes of Health (NIH) Training Grant appointment in the Department of Dermatology at Brigham and Women’s Hospital (5-T32-AR07098-31). K.-K.W. was supported by a Program of Research Excellence (SPORE) grant (P50 CA090578) and NIH grants (R01 AG2400401; R01 CA122794). The AQUA immunofluorescence study was supported by a grant from the NIH to D.L.R. (RO-1 CA 114277). This work is primarily supported by grants from the NIH to L.C. (RO1 CA93947; P50 CA93683).

Author Contribution O.K. identified GOLPH3 as an oncogene target of 5p13; K.L.S. performed oncogene validation and mechanistic studies; E.I. and A.P. performed TMA FISH analysis; H.R.W. and D.E.F. performed the HMEL anchorage-independent growth assay; S.D. and J.W. assisted with immunofluorescence assays and provided technical support; M.W. performed the co-immunoprecipitation assays; V.A. and D.L.R. performed AQUA analysis; S.C. assisted with cell culture studies; A.S. aided phospholipid and biochemical analyses; M.-C.L. and K.-K.W. performed rapamycin xenograft assays; Y.X. performed computational analyses; T.F. and J.H. provided technical support; L.C. supervised the experiments and data interpretation; K.L.S. and L.C. wrote the manuscript.

Author information

Author notes

    • Kenneth L. Scott
    •  & Omar Kabbarah

    These authors contributed equally to this work.

Affiliations

  1. Department of Medical Oncology,

    • Kenneth L. Scott
    • , Omar Kabbarah
    • , Mei-Chih Liang
    • , Joyce Wu
    • , Sabin Dhakal
    • , Min Wu
    • , Shujuan Chen
    • , Tamar Feinberg
    • , Joseph Huang
    • , Kwok-Kin Wong
    •  & Lynda Chin
  2. Belfer Institute for Applied Cancer Science,

    • Elena Ivanova
    • , Yonghong Xiao
    • , Alexei Protopopov
    •  & Lynda Chin
  3. Department of Pediatric Oncology, Dana-Farber Cancer Institute,

    • Hans R. Widlund
    •  & David E. Fisher
  4. Ludwig Center at Dana-Farber/Harvard Cancer Center, Boston, Massachusetts 02115, USA

    • Mei-Chih Liang
    •  & Kwok-Kin Wong
  5. Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06520, USA

    • Valsamo Anagnostou
    •  & David L. Rimm
  6. Department of Systems Biology, Harvard Medical School,

    • Abdel Saci
  7. Department of Dermatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA

    • Hans R. Widlund
    •  & Lynda Chin
  8. Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA

    • David E. Fisher

Authors

  1. Search for Kenneth L. Scott in:

  2. Search for Omar Kabbarah in:

  3. Search for Mei-Chih Liang in:

  4. Search for Elena Ivanova in:

  5. Search for Valsamo Anagnostou in:

  6. Search for Joyce Wu in:

  7. Search for Sabin Dhakal in:

  8. Search for Min Wu in:

  9. Search for Shujuan Chen in:

  10. Search for Tamar Feinberg in:

  11. Search for Joseph Huang in:

  12. Search for Abdel Saci in:

  13. Search for Hans R. Widlund in:

  14. Search for David E. Fisher in:

  15. Search for Yonghong Xiao in:

  16. Search for David L. Rimm in:

  17. Search for Alexei Protopopov in:

  18. Search for Kwok-Kin Wong in:

  19. Search for Lynda Chin in:

Corresponding author

Correspondence to Lynda Chin.

Supplementary information

PDF files

  1. 1.

    Supplementary Information

    This file contains Supplementary Tables 1-4 and Supplementary Figures S1-S5 with Legends.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nature08109

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.